aTYR PHARMA INC (ATYR) Stock Profile — Insider Trades & Financials

Revenue$190.0K

Net Income-$10.3M

EPS$-0.22

Market Cap$21.0M

Price Performance

Historical data including institutional events

Company Profile

Sanjay S Shukla

CEO & Executive Director

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.

Founded: 2005
Employees: 55
Headquarters: SAN DIEGO, CA, United States
Website: www.atyrpharma.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Feedback

Revenue$190.0K

Net Income-$10.3M

EPS$-0.22

Market Cap$21.0M

Price Performance

Historical data including institutional events

Company Profile

Sanjay S Shukla

CEO & Executive Director

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.

Founded: 2005
Employees: 55
Headquarters: SAN DIEGO, CA, United States
Website: www.atyrpharma.com

Peer ComparisonRevenue ($B)

▾

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER SELLJill Marie Broadfoot sold ATYRFeb 4, 2025

INSIDER SELLNancy Denyes sold ATYRFeb 4, 2025

INSIDER BUYJane A. Gross bought ATYRMar 17, 2025

INSIDER BUYPaul Schimmel bought ATYROct 8, 2025

INSIDER BUYPaul Schimmel bought ATYROct 9, 2025

INSIDER SELLNancy Denyes sold ATYRFeb 4, 2026

INSIDER SELLSanjay Shukla sold ATYRFeb 4, 2026

INSIDER SELLJill Marie Broadfoot sold ATYRFeb 4, 2026

INSIDER GRANT / AWARDPaul Schimmel (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDTimothy Coughlin (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDSara Zaknoen (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDEric Benevich (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDJane A. Gross (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDSvetlana Lucas (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER BUYPaul Schimmel (Director) BUY ATYRMay 27, 2026

INSIDER GRANT / AWARDBrandon Yaras (Chief Financial Officer) GRANT / AWARD ATYROct 1, 2026

⚡

Core Efficiency

ROE?

-21.13%

ROA?

-14.76%

Op. Margin?

-5726.84%

📊

Profitability Ratios

Net Margin?

-5425.79%

Current Ratio?

5.12

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 15, 2026 (in 33 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 15, 2026

Predicted10-Q

Aug 7, 2026

10-QQ2 202638d after period end

May 15, 2026

10-QQ1 202645d after period end

Mar 5, 2026

10-KQ4 202564d after period end

Mar 5, 2026

10-KFY 202564d after period end

Nov 6, 2025

10-QQ3 202537d after period end

Aug 7, 2025

10-QQ2 202538d after period end

May 7, 2025

10-QQ1 202537d after period end

Mar 13, 2025

10-KQ4 202472d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-07

SEC Metadata

2mo ago

Latest filing: 2026-08-07

Loading company sections...

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER SELLJill Marie Broadfoot sold ATYRFeb 4, 2025

INSIDER SELLNancy Denyes sold ATYRFeb 4, 2025

INSIDER BUYJane A. Gross bought ATYRMar 17, 2025

INSIDER BUYPaul Schimmel bought ATYROct 8, 2025

INSIDER BUYPaul Schimmel bought ATYROct 9, 2025

INSIDER SELLNancy Denyes sold ATYRFeb 4, 2026

INSIDER SELLSanjay Shukla sold ATYRFeb 4, 2026

INSIDER SELLJill Marie Broadfoot sold ATYRFeb 4, 2026

INSIDER GRANT / AWARDPaul Schimmel (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDTimothy Coughlin (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDSara Zaknoen (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDEric Benevich (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDJane A. Gross (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER GRANT / AWARDSvetlana Lucas (Director) GRANT / AWARD ATYRMay 11, 2026

INSIDER BUYPaul Schimmel (Director) BUY ATYRMay 27, 2026

INSIDER GRANT / AWARDBrandon Yaras (Chief Financial Officer) GRANT / AWARD ATYROct 1, 2026

⚡

Core Efficiency

ROE?

-21.13%

ROA?

-14.76%

Op. Margin?

-5726.84%

📊

Profitability Ratios

Net Margin?

-5425.79%

Current Ratio?

5.12

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 15, 2026 (in 33 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 15, 2026

Predicted10-Q

Aug 7, 2026

10-QQ2 202638d after period end

May 15, 2026

10-QQ1 202645d after period end

Mar 5, 2026

10-KQ4 202564d after period end

Mar 5, 2026

10-KFY 202564d after period end

Nov 6, 2025

10-QQ3 202537d after period end

Aug 7, 2025

10-QQ2 202538d after period end

May 7, 2025

10-QQ1 202537d after period end

Mar 13, 2025

10-KQ4 202472d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-07

SEC Metadata

2mo ago

Latest filing: 2026-08-07

aTYR PHARMA INC

Price Performance

Company Profile

aTYR PHARMA INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

aTYR PHARMA INC

Price Performance

Company Profile

The morning brief, before the bell.

aTYR PHARMA INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades